Synonym
Moperone Hydrochloride; EN-1733A; EN 1733A; EN1733A;
IUPAC/Chemical Name
1-(4-fluorophenyl)-4-(4-hydroxy-4-(p-tolyl)piperidin-1-yl)butan-1-one hydrochloride
InChi Key
RJTOSFZZYBCYTM-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H26FNO2.ClH/c1-17-4-8-19(9-5-17)22(26)12-15-24(16-13-22)14-2-3-21(25)18-6-10-20(23)11-7-18;/h4-11,26H,2-3,12-16H2,1H3;1H
SMILES Code
O=C(C1=CC=C(F)C=C1)CCCN2CCC(C3=CC=C(C)C=C3)(O)CC2.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
1050-79-9 (Moperone)
3871-82-7 (Moperone Hydrochloride)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
391.91
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lydecken K. [Report on the clinical testing of the delayed-action form of the neuroleptic agent moperone hydrochloride in 20 chronic psychotic patients]. Schweiz Arch Neurol Neurochir Psychiatr. 1977;120(1):75-82. German. PubMed PMID: 323966.
2: Quaglio MP, Bellini AM. A gas chromatographic method for the determination of fluanisone, moperone, aceperone and pipamperone in human plasma. Farmaco Prat. 1981 Apr;36(4):204-14. PubMed PMID: 6112157.
3: Heykants JJ, Lewi PJ, Janssen PA. On the distribution and metabolism of neuroleptic drugs. II. Pharmacokinetics of moperone. Arzneimittelforschung. 1970 Sep;20(9):1238-42. PubMed PMID: 5536800.
4: Janssen PA, Allewijn FT. The distribution of the butyrophenones haloperidol, trifluperidol, moperone, and clofluperol in rats, and its relationship with their neuroleptic activity. Arzneimittelforschung. 1969 Feb;19(2):199-208. PubMed PMID: 5818759.
5: Gross H, Kaltenbäck E. The clinical position of moperone among the butyrophenones. Nord Psykiatr Tidsskr. 1969;23(1):4-9. PubMed PMID: 5354545.
6: Seno H, Kumazawa T, Ishii A, Sato K, Suzuki O. Determination of some butyrophenones in body fluids by gas chromatography with surface ionization detection. Nihon Hoigaku Zasshi. 1993 Oct;47(5):367-71. PubMed PMID: 8258900.
7: Imamura Y, Koga T, Higuchi T, Otagiri M, Sugino E, Hibino S. Inhibitory effect of drugs with a ketone group on reduction of acetohexamide catalyzed by carbonyl reductase from rabbit kidney. J Enzyme Inhib. 1997 Feb;11(4):285-92. PubMed PMID: 9208371.
8: Chiou GC. Treatment of ocular hypertension and glaucoma with dopamine antagonists. Ophthalmic Res. 1984;16(3):129-34. PubMed PMID: 6147806.
9: Chiou GC, Chen YJ. Improvement of ocular blood flow with dopamine antagonists on ocular-hypertensive rabbit eyes. Zhongguo Yao Li Xue Bao. 1992 Nov;13(6):481-4. PubMed PMID: 1302433.
10: Chiou GC, Yan HY. Effects of antiglaucoma drugs on the blood flow in rabbit eyes. Ophthalmic Res. 1986;18(5):265-9. PubMed PMID: 3808590.
